Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11833150 Methods of treating liver disease

Patent 11833150 was granted and assigned to Gilead Sciences on December, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Gilead Sciences

0

Current Assignee

Gilead Sciences

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

David Gordon Clarkson Breckenridge0

John T. Liles0

Jamie Geier Bates0

Date of Patent

December 5, 2023

0

Patent Application Number

168038240

Date Filed

February 27, 2020

0

Patent Citations

US Patent 8193192 Heterocyclic FXR binding compounds

0

US Patent 8222256 Methods of using IGFIR and ABL kinase modulators

0

US Patent 8952042 FXR (NR1H4) binding and activity modulating compounds

0

US Patent 8969557 ACC inhibitors and uses thereof

0

US Patent 9139539 FXR (NR1H4) binding and activity modulating compounds

0

US Patent 9346822 Thienopyrimidine compounds and use thereof

0

US Patent 9453026 ACC inhibitors and uses thereof

0

US Patent 9539244 FXR (NR1H4) binding and activity modulating compounds

0

...

Patent Primary Examiner

Jeffrey S Lundgren

0

CPC Code

0

0

Patent abstract

The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ACC inhibitor in combination with an FXR agonist to a patient in need thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11833150 Methods of treating liver disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool